Cure My Disease

Don't miss your cure!

 Log in / Sign up

Which additive keeps hernia pain away longer?

NCT ID NCT07837492

Symptom relief Sponsor: Assiut University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 23, 2026 · Last updated Sep 24, 2026 · Updated 1 time

Summary

Researchers test whether adding dexmedetomidine or nalbuphine to a standard numbing drug makes a nerve block last longer after inguinal hernia repair. Adults having this surgery under spinal anesthesia receive one of three mixtures: bupivacaine alone, bupivacaine with nalbuphine, or bupivacaine with dexmedetomidine. The team measures how long until patients first ask for more pain relief and tracks pain scores, medication use, and side effects over 24 hours.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
dexmedetomidine and nalbuphine added to bupivacaine for nerve blocks
What this could lead to
If one additive works better, it could give patients longer pain relief after hernia surgery and reduce the need for additional painkillers.
What could go wrong
The trial is small and focuses on one type of surgery. The results may not apply to other operations or patients, and side effects could differ between the additives.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 102 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Nov 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18 to 65 years * American Society of Anesthesiologists (ASA) physical status I or II * Scheduled for elective unilateral primary inguinal hernia repair under spinal anesthesia supplemented with ilioinguinal-iliohypogastric nerve block * Body weight between 45 and 100 kg and body mass index (BMI) \<= 35 kg/m\^2 * Ability to understand the study protocol, comply with study requirements, and communicate pain intensity using the Visual Analog Scale (VAS) Exclusion Criteria: * Known allergy or hypersensitivity to amide-type local anesthetics, dexmedetomidine, or nalbuphine * Contraindications to spinal anesthesia (e.g., severe hypovolemia, elevated intracranial pressure, active infection at the lumbar puncture site, severe spinal deformity) * History of neurological disorders (e.g., peripheral neuropathy, myopathy, seizure disorders, or cognitive impairment) * Coagulopathy, concurrent anticoagulant therapy, or local infection at the block site contraindicating regional anesthesia * Severe hepatic, renal, or cardiovascular disease (e.g., heart block, uncontrolled hypertension, ischemic heart disease, severe valvular disease, chronic renal failure, or liver cirrhosis) * History of opioid or substance abuse * Emergency surgical procedures * Procedures expected to exceed 3 hours or requiring conversion to general anesthesia

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Inguinal hernia are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Hernia, Inguinal Pain, Postoperative

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Inguinal hernia Postoperative pain

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.